Slide

Mainstay Medical Announces US$108 Million Equity Financing Transaction

Mainstay Medical Holdings plc today announced the closing of an equity financing in which it raised gross proceeds of US$108 million. Mainstay intends to use the funds to support the company’s commercial launch of ReActiv8® in the U.S., continued expansion in Europe and Australia, additional post-market clinical studies and research, and general operations.